Cargando…

Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf(V600E) Melanoma

Melanoma patients harboring the BRAF(V600E) mutation are treated with vemurafenib. Almost all of them ultimately acquire resistance, leading to disease progression. Here, we find that a small molecule from a marine sponge, panicein A hydroquinone (PAH), overcomes resistance of BRAF(V600E) melanoma c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Signetti, Laurie, Elizarov, Nelli, Simsir, Méliné, Paquet, Agnès, Douguet, Dominique, Labbal, Fabien, Debayle, Delphine, Di Giorgio, Audrey, Biou, Valérie, Girard, Christophe, Duca, Maria, Bretillon, Lionel, Bertolotto, Corine, Verrier, Bernard, Azoulay, Stéphane, Mus-Veteau, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352342/ https://www.ncbi.nlm.nih.gov/pubmed/32526884 http://dx.doi.org/10.3390/cancers12061500

Ejemplares similares

Methiothepin Increases Chemotherapy Efficacy against Resistant Melanoma Cells
por: Durand, Nelly, et al.
Publicado: (2021)

Astemizole Sensitizes Adrenocortical Carcinoma Cells to Doxorubicin by Inhibiting Patched Drug Efflux Activity
por: Hasanovic, Anida, et al.
Publicado: (2020)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

Preclinical Evaluation of Vemurafenib as Therapy for BRAF(V600E) Mutated Sarcomas
por: Gouravan, Sarina, et al.
Publicado: (2018)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
por: Sapkota, Bishu, et al.
Publicado: (2013)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)

Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement
por: Wang, Xiaomeng, et al.
Publicado: (2023)

Heterologous Expression and Purification Systems for Structural Proteomics of Mammalian Membrane Proteins
por: Mus-Veteau, Isabelle
Publicado: (2002)

Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF(V600) melanoma cells
por: Smith, Lorey K., et al.
Publicado: (2020)

Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
por: Cai, Chao, et al.
Publicado: (2021)

Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH
por: Evseev, Dmitry, et al.
Publicado: (2023)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
por: del Bufalo, Francesca, et al.
Publicado: (2014)

Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency
por: Hasanovic, Anida, et al.
Publicado: (2018)

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
por: Goodall, Megan L, et al.
Publicado: (2014)

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
por: Car, Iris, et al.
Publicado: (2023)

Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib
por: Lehraiki, Abdelali, et al.
Publicado: (2015)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

The clinical response to vemurafenib in a patient with a rare BRAF(V600DK601del) mutation-positive melanoma
por: Trudel, Stéphanie, et al.
Publicado: (2014)

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
por: Sahadudheen, K., et al.
Publicado: (2016)

Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF(V600E)-Specific Inhibitor)
por: Torres-Collado, Antoni Xavier, et al.
Publicado: (2018)

Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report
por: Dooley, Andrew J., et al.
Publicado: (2016)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
por: Cho, Su Min, et al.
Publicado: (2021)

Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells
por: Jiang, Suyuan, et al.
Publicado: (2022)

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation
por: Oneal, Patricia A., et al.
Publicado: (2018)

The Hedgehog Receptor Patched Is Involved in Cholesterol Transport
por: Bidet, Michel, et al.
Publicado: (2011)

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
por: Gibney, Geoffrey T, et al.
Publicado: (2015)

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation–positive melanoma
por: Dréno, Brigitte, et al.
Publicado: (2018)

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
por: Chapman, P B, et al.
Publicado: (2017)

Vemurafenib in Chinese patients with BRAF(V600) mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
por: Si, Lu, et al.
Publicado: (2018)

EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF(V600E) Mutated Parent- and Vemurafenib-Resistant Melanoma
por: Fu, Yige, et al.
Publicado: (2019)

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting
por: Carroll, Molly J., et al.
Publicado: (2019)

Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets
por: Tóvári, József, et al.
Publicado: (2023)

Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature
por: Garnier, Louis, et al.
Publicado: (2019)

HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF(V600E) Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
por: Furfaro, Anna Lisa, et al.
Publicado: (2022)

Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing BRAF(V600E) -Mutated Erdheim–Chester Disease: A Case Report
por: Razanamahery, Jérôme, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gtrepak39neuftjql5ldtkjce4